13th Annual Meeting of the Safety Pharmacology Society: Focus on novel technologies and safety pharmacology frontiers

Expert Opinion on Drug Safety

Volumn 13, Issue 9, 2014, Pages 1271-1281

  Cavero, Icilio ^a  

^a NONE   (France)

Author keywords

Anticancer agents; CiPA; Comprehensive in vitro proarrhythmia assay; ECG history; Epigenetics; Functional foods; HDACis; Probiotics; Safety pharmacology.

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; ION CHANNEL; PROBIOTIC AGENT;

ACTION POTENTIAL; ARTICLE; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ELECTROCARDIOGRAM; EPIGENETICS; FUNCTIONAL FOOD; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; MEDICAL SOCIETY; NONHUMAN; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; ADVERSE DRUG REACTION; ANIMAL; COMPUTER SIMULATION; DAIRY PRODUCT; MEDICAL TECHNOLOGY; PHARMACOLOGY; PROCEDURES;

ANIMALS; BIOMEDICAL TECHNOLOGY; COMPUTER SIMULATION; DAIRY PRODUCTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FUNCTIONAL FOOD; HUMANS; PHARMACOLOGY; PROBIOTICS;

EID: 84906264443     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.940310     Document Type: Article

References (64)

1. Cavero I, Crumb W. Safety Pharmacology Society: 5th Annual Meeting, 27 - 29 September, 2005, Mannheim, Germany. Expert Opinion Drug Saf 2006;5:181-5
2. Cavero I. Safety Pharmacology Society: 6th Annual Meeting 26-28 September, 2006, San Diego, USA. Expert Opinion Drug Saf 2007;6:87-92
3. Cavero I. Safety Pharmacology Society: 7th Annual Meeting 19-20 September, 2007, Edinburgh, UK. Expert Opinion Drug Saf 2008;7:91-100
4. Cavero I. Safety Pharmacology Society: 8th Annual Meeting 22-25 September, 2008, Madison, USA. Expert Opinion Drug Saf 2009;8:1-11
5. Cavero I. Safety Pharmacology Society: 9th Annual Meeting 15-18 September, 2009, Strasbourg, France. Expert Opin Drug Saf 2010;9:365-78
6. Cavero I. 10th Annual Meeting of the Safety Pharmacology Society: an overview. Expert Opin Drug Saf 2011;10:319-33
7. Cavero I. 2011 Annual Meeting of the Safety Pharmacology Society: an overview. Expert Opin Drug Saf 2012;11:341-53
8. Cavero I. 2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines. Expert Opin Drug Saf 2013;12:589-603
9. Fisch C. Centennial of the string galvanometer and the electrocardiogram. J Am Coll Cardiol 2000;36:1737-45
10. Fye WB. A history of the origin, evolution, and impact of electrocardiography. Am J Cardiol 1994;73:937-49
11. Rivera-Ruiz M, Cajavilca C, Varon J. Einthoven's string galvanometer: the first electrocardiograph. Tex Heart Inst J 2008;35:174-8
12. Kligfield P. The centennial of the Einthoven electrocardiogram. J Electrocardiol 2002;35(Suppl):123-9
13. Barold SS. Willem Einthoven and the birth of clinical electrocardiography a hundred years ago. Card Electrophysiol Rev 2003;7:99-104
14. Einthoven W. Le telecardiogramme. Arch Int Physiol 1906;4:132-64.
15. English translation: Mathewson FAL, Jackh H. Heart J 1955;49:77-82
16. Einthoven W. Weiteres über das elecktrokardiogramm. Pflugers Arch 1908;122:517-84
17. Kahn JK, Howell JD. Frank Norman Wilson. Clin Cardiol 1987;10:616-18
18. Lewis T. Clinical electrocardiography. 1913. Available from: https://archive.org/details/clinicalelectroc00lewiuoft [Accessed date June 2014]
19. Lewis T. The mechanism and the registration of the heart beat. 1920.edition (a first edition was published in 1911) Available from: https://archive.org/stream/mechanismgraphic00lewi [Accessed date June 2014]
20. Lewis T. Clinical disorders of the heart. 1912. Available from: https://archive.org/details/clinicaldisorde03lewigoog [Accessed date June 2014]
21. Shapiro E. The first textbook of electrocardiography. Thomas Lewis: Clinical Electrocardiography. J Am Coll Cardiol 1983;1:1160-1
22. ICH Harmonised Tripartite Guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. S7B. 2005. Available from: www.ich.org/products/ guidelines/safety/article/safetyguidelines.html [Accessed date June 2014]
23. ICH Harmonised Tripartite Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. E14. 2005. Available from: www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E14/E14-Guideline.pdf [Accessed date June 2014]
24. Cavero I, Holzgrefe H. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative. Expert Opin Drug Saf 2014;13:745-58
25. Rampe D, Brown AM. A history of the role of the hERG channel in cardiac risk assessment. J Pharmacol Toxicol Methods 2013;68:13-22
26. Sager PT, Gintant G, Turner JR, et al. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 2014;16:292-300
27. Stockbridge N. Benefits and limitations overview. 2013. Available from: www.hesiglobal.org/files/1%20Stockbridge.pdf [Accessed date June 2014]
28. Van Bortle K, Corces VG. Nuclear organization and genome function. Annu Rev Cell Dev Biol 2012;28:163-87
29. Hübner MR, Eckersley-Maslin MA, Spector DL. Chromatin organization and transcriptional regulation. Curr Opin Genet Dev 2013;23:89-95
30. de Graaf CA, van Steensel B. Chromatin organization: form to function. Curr Opin Genet Dev 2013;23:185-90
31. Li G, Reinberg D. Chromatin higherorder structures and gene regulation. Curr Opin Genet Dev 2011;21:175-86
32. Campos EI, Reinberg D. Histones: annotating chromatin. Annu Rev Genet 2009;43:559-99
33. Hedhli N, Russell KS. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev 2011;7:221-33
34. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277:8-21
35. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5:981-9
36. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21:1790-802
37. de Git KC, de Boer TP, Vos MA, et al. Cardiac ion channel trafficking defects and drugs. Pharmacol Ther 2013;139:24-31
38. Balse E, Steele DF, Abriel H, et al. Dynamic of ion channel expression at the plasma membrane of cardiomyocytes. Physiol Rev 2012;92:1317-58
39. Kuryshev YA, Ficker E, Wang L, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 2005;312:316-23
40. Cordes JS, Sun Z, Lloyd DB, et al. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 2005;145:15-23
41. Wan X, Dennis AT, Obejero-Paz C, et al. Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome. J Biol Chem 2011;286:2843-52
42. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009;28:233-41
43. Japan Ministry of Health, Labour and Welfare. Food for Specified Health Uses (FOSHU). Available from: www.mhlw.go.jp/english/topics/foodsafety/fhc/02. html [Accessed date June 2014]
44. Howlett J, Edwards DG, Cockburn A, et al. The safety assessment of novel foods and concepts to determine their safety in use. Int J Food Sci Nutr 2003;54:S1-S32
45. Hepburn P, Howlett J, Boeing H, et al. The application of post-market monitoring to novel foods. Food Chem Toxicol 2008;46:9-33
46. Sanders ME. How do we know when something called "probiotic" is really a probiotic? A Guideline for consumers and health care professionals. Funct Food Rev 2009;1:3-12
47. ICH Harmonised Tripartite Guideline. Safety pharmacology studies for human pharmaceuticals. S7A. 2000. Available from: www.ich.org/fileadmin/Public- Web-Site/ICH-Products/Guidelines/Safety/S7A/Step4/S7A-Guideline.pdf [Accessed date June 2014]
48. Vankerckhoven V, Huysb G, Vancanneyt M, et al. Biosafety assessment of probiotics used for human consumption: recommendations from the EU-PROSAFE project. Trend Food Sci Tech 2008;19:102-14
49. Salminen S, von Wright A, Morelli L, et al. Demonstration of safety of probiotics -a review. Int J Food Microbiol 1998;44:93-106
50. Moreillon P, Que YA. Infective endocarditis. Lancet 2004;363(9403):139-49
51. EFSA. Technical guidance. Update of the criteria used in the assessment of bacterial resistance to antibiotics of human or veterinary importance. Prepared by the panel on additives and products or substances used in animal feed. Adopted 2008. Available from: www.efsa.europa.eu/fr/efsajournal/doc/732. pdf [Accessed date June 2014]
52. Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 200: safety of Probiotics to Reduce Risk and Prevent or Treat Disease. 2011. Available from: www.ahrq.gov/research/findings/evidencebased- reports/probiotic-evidence-report.pdf [Accessed date June 2014]
53. Lewis T. Observations upon disorders of the heart's action. Heart 1912;3:279-309
54. Toxicity Testing in the 21st Century: a vision and a strategy. National Research Council. National Academies Press, Washington, DC; 2007
55. Seurat-1. Towards the replacement of in vivo repeated dose systemic toxicity testing. Available from: www.seurat-1.eu/ [Accessed date June 2014]
56. Jonsson MK, Vos MA, Mirams GR, et al. Application of human stem cellderived cardiomyocytes in safety pharmacology requires caution beyond hERG. J Mol Cell Cardiol 2012;52:998-1008
57. Roden DM, Hong CC. Stem cell-derived cardiomyocytes as a tool for studying proarrhythmia: a better canary in the coal mine? Circulation 2013;127:1641-3
58. Guo L, Coyle L, Abrams RM, et al. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci 2013;136:581-94
59. Himmel HM. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds. J Pharmacol Toxicol Methods 2013;68:97-111
60. Abassi YA, Xi B, Li N, et al. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br J Pharmacol 2012;165:1424-41
61. Mehta A, Sequiera GL, Ramachandra CJ, et al. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. Cardiovasc Res 2014;102:497-506
62. Siró I, Kápolna E, Kápolna B, et al. Functional food. Product development, marketing and consumer acceptance-a review. Appetite 2008;51:456-67
63. Saad N, Delattre C, Urdaci M, et al. An overview of the last advances in probiotic and prebiotic field. LWT - Food Sci and Technol 2013;50:1-16
64. Saarela M, Mogensen G, Fondén R, et al. Probiotic bacteria: safety, functional and technological properties. J Biotechnol 2000;84:197-215